Vitrolife — M&A Activity 2012

Oct 4, 2012

Press release October 4, 2012 Gothenburg

Vitrolife completes acquisition of Cryo Management Ltd

On June 29 Vitrolife announced that the company had entered into an agreement to acquire 100% ownership in Cryo Management Ltd. Vitrolife has now completed the transaction and Cryo Management Ltd is now a part of Vitrolife.

Cryo Management Ltd is one of the world's leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. The company has approximately 20 employees and is based in Hungary. The acquisition was completed under essentially the same conditions as were communicated on June 29.

"We are pleased to be able to welcome our new colleagues within Cryo to the Vitrolife Group. There continues to be great and increasing interest in the market for the company's product for the monitoring of embryos, Primo Vision, and we look forward to being able to offer this world-leading product to current and new customers," says Thomas Axelsson, CEO.

October 4, 2012 VITROLIFE AB (publ) Thomas Axelsson, CEO

Queries should be addressed to:

Thomas Axelsson, CEO, phone +46 31 721 80 01 Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is a global biotechnology/medical device Group. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in ca 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

______________________________________________________________________________________________________________________

___________________________________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 4, 2012 at 04:30 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.